Decisions about add-on reimbursement for medical devices in France in July and August 2019

23

Sep 2019

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of many medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in July and August 2019.

Nine (9) decisions were released regarding orthopedic devices:

  • OSSDSIGN Cranial PSI, custom bone substitute for the reconstruction of the cranial vault (application for registration, approved)
  • TMARS, acetabular reconstruction system (application for registration, approved)
  • LP ESP II, a lumbar intervertebral prosthesis (canceled)
  • VELOCITY, class III energy recovery foot (application for registration, approved)
  • CELSUS, class III energy recovery foot (application for registration, approved)
  • PEEK, custom bone substitute for cranial reconstruction (application for registration, approved)
  • LP ESP (version II), the total prosthesis of the lumbar disc (renewal of registration, approved)
  • FOOT RUSH ROVER PROTEOR, class II energy release foot (application for registration, approved)
  • FOOT RUSH PROTEOR for children, child’s energy release foot (application for registration, approved)

Fifteen (15) decisions were released for cardiovascular devices:

  • SURPASS EVOLVE, a self-expanding intracranial stent with controlled release (said flow diverter) (application for registration, approved)
  • STELLAREX, paclitaxel-eluting balloon (application for modification of the registration conditions, approved)
  • FRED and FRED Jr, self-expanding intracranial stents with controlled release (said flow diverter) (application for registration, approved)
  • SURPASS STREAMLINE, a self-expanding intracranial stent with controlled release (said flow diverter) (application for registration, approved)
  • ZENITH Windows and Multibranche, thoracoabdominal stents (application for registration, approved)
  • RELAY PLUS, thoracic aortic stent (application for registration, approved)
  • RELAY NBS PLUS, thoracic aortic stent (application for registration, approved)
  • Flex Pipeline with Shield Technology, a self-expanding intracranial stent with controlled release (said flow diverter) (application for registration, approved)
  • ZENITH FENESTRATED, windowed aortic stent (renewal of registration, approved)
  • MRI SR ACCOLADE, single-frequency rate implantable cardiac pacemaker associated with the LATITUDE NXT Remote monitoring system (application for registration, approved)
  • MRI DR ACCOLADE, double-chamber frequency-locked implantable cardiac pacemaker associated with the LATITUDE NXT telemonitoring system (application for registration, approved)
  • IRM DR EL ACCOLADE, double-chamber frequency-locked implantable cardiac pacemaker associated with the LATITUDE NXT telemonitoring system (application for registration, approved)
  • VISIONIST (model U225) associated with the LATITUDE NXT remote monitoring system, implantable cardiac pacemaker with atrio-biventricular pacing for "triple chamber" resynchronization associated with the LATITUDE NXT remote monitoring system (application for registration, approved)
  • VISIONIST (model U226) associated with the LATITUDE NXT remote monitoring system, implantable cardiac pacemaker with atrio-biventricular pacing for "triple chamber" resynchronization associated with the LATITUDE NXT remote monitoring system (application for registration, approved)
  • VISIONIST (model U228) associated with the LATITUDE NXT remote monitoring system, implantable cardiac pacemaker with atrio-biventricular pacing for "triple chamber" resynchronization associated with the LATITUDE NXT remote monitoring system (application for registration, approved)

Five (5) decisions were released for other devices:

  • DC BEAD, controlled release microbead of active substance for hepatic arterial chemoembolization (application for registration, approved)
  • PONTO 4, processors for osteo-integrated hearing prosthesis (application for registration, approved)
  • I-neb AAD, ultrasonic nebulization system (application for registration, rejected because he available data do not establish the interest)
  • Invacare G-trac, trajectory control system for electric wheelchairs INVACARE (application for registration, rejected due to the absence of clinical data)
  • GLUCOFIX PREMIUM, device for automatic reading of the blood glucose and ketonemia and GLUCOFIX b-KETONE SENSOR, associated test strips (renewal of registration, approved)

See the list of decisions in French here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more